KANSAS CITY, Kan. and BOSTON, Dec. 11, 2013 /PRNewswire/ -- Aratana Therapeutics (NASDAQ: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced that it will participate in three upcoming investor events. On Monday, December 16, 2013, the company will present at the Bank of America Merrill Lynch 2013 Animal Health Summit, as well as an investor dinner hosted by Stifel as part of its Med-Tech Madness Bus Trip. Aratana will also participate in the Guggenheim Securities Boston Healthcare Conference, to be held Tuesday, December 17, 2013.
During these events, Aratana will host one-on-one and small group meetings with investors.
|
Event: |
Bank of America Merrill Lynch 2013 Animal Health Summit | |||||
|
Date: |
Monday, December 16, 2013 | |||||
|
Presentation: |
8:55 am (Eastern Time) | |||||
|
Location: |
Bank of America Merrill Lynch Conference Center; Boston, MA | |||||
|
Event: |
Stifel Med-Tech Madness Bus Trip Dinner | |||||
|
Date: |
Monday, December 16, 2013 | |||||
|
Presentation: |
6pm (Pacific Time) | |||||
|
Location: |
Four Seasons Hotel; Palo Alto, CA | |||||
|
Event: |
Guggenheim Securities Boston Healthcare Conference | |||||
|
Date: |
Tuesday, December 17, 2013 | |||||
|
Presentation: |
n/a (1x1 meetings only) | |||||
|
Location: |
The Langham Hotel; Boston, MA | |||||
About Aratana Therapeutics
Aratana Therapeutics is a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.
Contacts:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664
Andrew Mielach (media)
amielach@tiberend.com; (212) 375-2694
SOURCE Aratana Therapeutics